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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
preprandial oral lactase supplement reduces abdominal pain in lactose-intolerant adult patients 
after a lactose-containing meal. 
 
STUDY DESIGN: A systematic review of three randomized, blinded, controlled primary 
research studies published between the years of 2010 and 2018. 
 
DATA SOURCES: One randomized controlled trial (RCT), one randomized comparative study, 
and one randomized crossover study evaluating the efficacy of 9,000 units of preprandial oral 
lactase supplement in reducing abdominal pain due to lactose intolerance (LI). All studies were 
published in peer-reviewed journals and found via the use of PubMed, Elsevier, and OVID. The 
particular articles were selected based on their novelty and relevance to the clinical question. 
 
OUTCOMES MEASURED: LI patients used a visual analogue scale questionnaire and 
maintained a diary to report the severity of their symptoms, tolerability, and adverse events. 
Clinical investigators evaluated compliance and calculated a symptom score. 
 
RESULTS: Ojetti et al. reported a large reduction in abdominal pain in the tilactase group 
comparing to the placebo group. De Vrese et al. found no significant reduction in abdominal pain 
with Aspergillus oryzae lactase treatment. Francesconi et al. proved an experimental Perlatte® to 
be non-inferior to a commercially available Lactaid®, however, the difference between the two 
products was not statistically significant. 
 
CONCLUSIONS: The evidence presented in this review is conflicting as to whether or not 
preprandial oral lactase supplement reduces abdominal pain in LI adult patients after a lactose-
containing meal. The future research should consider genetic testing of the participants and 
distinguishing subjective lactose intolerance symptoms from a true lactase deficiency. 
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INTRODUCTION 
Lactose intolerance (LI) is a clinical syndrome of lactase deficiency with the most 
frequent complaint being abdominal pain, followed by: diarrhea, flatulence, bloating, headache, 
fatigue, and muscle or joint pain. In the United States, the prevalence of LI is estimated to be 
15% among Caucasians, 80% among African Americans, and up to 53% in the Hispanic 
population.1,2 Being one of the most common genetic diseases in the Western world,3 LI requires 
dietary restriction and careful meal planning by those who are affected, and it may negatively 
affect the quality of life for such individuals.  
An exact number for the annual cost of LI has yet to be determined. A proper evaluation 
of LI comprises of a primary care visit, a gastroenterologist visit, a hydrogen breath test, a blood 
glucose or a stool acidity tests, and a nutritionist’s consultation at a minimum. A dairy-free diet, 
as well as calcium and vitamin D fortified products, come at an additional cost. The available 
over-the-counter Lactaid supplement currently retails at approximately $0.25/caplet, while 
calcium and vitamin D supplements approximately cost $0.10/tablet.4 Furthermore, LI-associated 
hypocalcemia and low vitamin D intake leads to an increased public health burden from 
fractures, osteoporosis, and rickets in children.1,2,5-7 According to the recent report by the Health 
Care Cost Institute, between the years of 2012 and 2016, there has been a 129% increase in 
physician assistant (PA) and nurse practitioner (NP) primary care visits.8 This places PAs at the 
front line of recognizing and treating LI in a primary care setting, as well as providing 
gastroenterology referrals. 
LI results from a deficiency of a brush border enzyme responsible for lactose hydrolysis 
to glucose and galactose in the small intestine. When intestinal lactase level is low, lactose 
catabolism is disrupted. As such, lactose remains in the bowel lumen and draws water due to 
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osmotic force, which ultimately results in gastrointestinal (GI) symptoms. The four main types of 
LI include: primary LI (absent or reduced lactase activity from birth known as galactosemia), 
secondary LI (due to digestive tract inflammation), late onset lactase deficiency (decrease in 
lactase with aging), and temporary lactose malabsorption in newborns (physiological).1,2  
Because LI can manifest itself at any age and is diet-dependent, this condition is often 
underreported and the diagnosis is often delayed or attributed to other conditions such as irritable 
bowel syndrome (IBS) or gastroesophageal reflux. Once recognized, LI requires individualized 
treatment because it depends on the person’s genetic expression of the lactase gene, GI bacterial 
flora and motility, as well as the individual’s perception of the symptom severity and its 
interference with daily activities. In addition, there is a wide spectrum of the doses of ingested 
lactose needed to produce symptoms in patients, which makes it difficult to develop a universal 
approach to LI treatment. The primary existing method of treatment is implementation of dairy-
free and low fermentable oligo-, di-, monosaccharides and polyols (FODMAP) diets. However, 
such an approach of avoiding lactose-containing foods is restrictive, cost-ineffective, and carries 
a certain health risk for LI patients, as described in the previous paragraphs.  
A promising and seemingly cost-effective treatment method evaluated in this review is 
the oral exogenous lactase supplement. For instance, Lactaid® is currently recognized as “safe 
for human consumption”9 by the Food and Drug Administration (FDA), however, it has not yet 
been approved for medical use in the United States. If the exogenous lactase supplement is 
indeed proven to be effective for GI symptoms reduction, specifically abdominal pain, it could 
minimize vitamin D and calcium-associated deficiencies in the LI population and decrease 
overall public health burden.  
OBJECTIVE 
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The objective of this selective EBM review is to determine whether or not preprandial 
oral lactase supplement reduces abdominal pain in lactose-intolerant adult patients after a 
lactose-containing meal. 
METHODS 
The review included two randomized placebo-controlled clinical trials and one 
randomized comparative non-inferiority study published between the years of 2010 and 2018. 
The literature search was conducted using the following keywords: “lactose intolerance”, 
“lactose malabsorption”, “hypolactasia”, and “lactase supplement” in PubMed, Elsevier, and 
OVID databases. The search solely included randomized, blinded, controlled clinical trials 
published within 10 years. Excluded were the studies released over ten years ago, non-
randomized studies, and studies that included products unavailable in the U.S. All articles were 
published in peer-reviewed journals in English. Francesconi et al. was co-published in 
Portuguese. The articles were selected based on their novelty and relevance to the clinical 
question. The selected studies utilized mean change from baseline, standard deviation (SD), P 
value, chi-squared test (X2), relative risk reduction (RRR), absolute risk reduction (ARR), and 
number-needed-to-treat (NNT) to report the statistics. All study participants were older than 18 
years of age who considered themselves lactose malabsorbers or with an existing diagnosis of 
primary hypolactasia, have not had a recent surgery or colonoscopy, and without a known GI 
comorbidities and substance abuse. Table 1 on the next page depicts the specific demographics 
and characteristics of each study. 
To simulate lactose malabsorption, the experimental group in each study ingested 
preprandial lactase, while the control group received a visually identical placebo or reference 
product. Specifically, Ojetti et al.6 administered 9,000 U of tilactase to their study participants, 
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followed by 25 g of lactose after 15 minutes. De Vrese et al.7 patients ingested 9,000 FCC of 
Aspergillus oryzae-derived lactase together with 12.5 g of lactose. Both Ojetti et al. and De 
Vrese et al. administered visually identical placebo to their control groups.6,7 Francesconi et al. 
administered 9,000 FCC of oral lactase (Perlatte®) to the experimental group and 9,000 FCC of 
Lactaid® to the control group and stated that all of the participants had “a major meal” after 
lactase ingestion.5 In all three studies, the measured outcomes were reduction of incidence and 
severity of abdominal pain in LI patients. The severity of patient symptoms, tolerability of 
treatment, and the occurrence of adverse events were recorded via the Visual Analogue Scale 
(VAS). In addition, patients either noted their LI symptoms in a diary, or they were evaluated in-
person, or both. Finally, investigators evaluated patient compliance and calculated a total 
symptom score. All three studies were approved by the local ethics research committees.  
OUTCOMES MEASURED 
The outcome measured was reduction of incidence and severity of abdominal pain after 
oral administration of lactase to LI patients before meals. In both the Ojetti et al. and Francesconi 
et al. studies,5,6 patients recorded their GI symptoms in a diary. Symptoms were then assessed by 
VAS from 0-10 with 0 being “absent” and 10 being “severe” symptoms. For each patient, a score 
was calculated for abdominal pain. De Vrese et al. patients filled out a similar questionnaire 
where each symptom was evaluated on frequency, intensity, and duration and rated on a 0-6 
scale with 0 being “no symptoms” and 6 being “unbearable” symptoms.7 
RESULTS 
 All three of the studies compared adult patients of any gender or ethnicity in an 
experimental group receiving 9,000 units of preprandial lactase to a control group receiving a 
placebo (Ojetti et al. and De Vrese et al.) or a reference product Perlatte® (Francesconi et al.).  
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In addition, the multi-arm studies by Ojetti et al. and De Vrese et al. reported data from treatment 
with multiple doses of lactase and reference products,6,7 however, for the purpose of this review, 
only data from 9,000 FCC lactase compared to a placebo experiments will be analyzed.  
Table 1 - Demographics and Characteristics of Included Studies  
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
criteria 
Exclusion 
criteria 
W/D Intervention 
Fran-
cesco-
ni et 
al., 
20165 
Rando-
mized 
compa-
rative 
non-
inferio-
rity study 
128 18-
60 
Existing 
diagnosis of 
primary 
hypolactasia 
History of 
smoking, 
colonoscopy or 
enema in the 
prior four weeks, 
GI 
comorbidities, 
lactase allergy 
21 Administration 
of 9,000 FCC 
of oral 
exogenous 
lactase 
(Perlatte®) 
before 
breakfast, 
lunch, and 
dinner for 42 
days 
Ojetti 
et al., 
20106 
RCT 60 18-
65 
Adults with 
GI 
symptoms 
after lactose 
ingestion and 
positive to 
the hydrogen 
lactose 
breath test 
Age <18 or >65 
years; diagnosis 
of small 
intestinal 
bacteria 
overgrowth; 
history of allergy 
to milk proteins 
0 One-time 
administration 
of 4 pills of 
tilactase (9000 
U) PO  15 min 
before the 
control lactose 
breath test, 
followed by 25 
grams of 
lactose PO 
De 
Vrese 
et al., 
20157 
Rando-
mized 
crossover 
study 
30 > 18   Adults who 
consider 
themselves 
lactose 
maldigesters 
or with an 
existing 
diagnosis of 
lactose 
maldigestion 
Participation in 
another clinical 
trial within 30 
days, surgery 
within the last 3 
months, known 
metabolic or GI 
disorder and/or 
medication for it, 
psychiatric 
disorder, or 
substance abuse 
6 Ingestion of 
one capsule of 
9000 FCC acid 
lactase from 
Aspergillus 
oryzae together 
with 150 ml of 
milk fortified 
with 5 g of 
lactose on five 
days separated 
by four periods 
of two-week 
wash-outs 
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Patients in all studies had to have an existing diagnosis of lactose maldigestion or a 
history of GI symptoms after lactose ingestion. Furthermore, they had to test positive to the 
hydrogen lactose breath test, which is a standardized quantitative measure of lactose 
malabsorption. History of substance abuse, milk protein allergy, GI comorbidity or recent 
intervention were universally considered as exclusion criteria due to non-specificity of GI 
symptoms and risk of impaired digestion and skewed data. A complete set of inclusion and 
exclusion criteria can be found in Table 1 above. In each study, the qualified subjects were 
required to undergo the lactose hydrogen breath test at every visit to ensure compliance with the 
interventions.  
The Ojetti et al. study6 was performed at a study center and lasted eight hours of one day. 
Sixty patients were randomized to three 20 patients-treatment groups: the tilactase group, the 
placebo group, and the Lactobacillus reuteri group. All patients in all groups completed the 
study. Refer to Table 2 below for a summary of results from this study. X2 and Fisher’s exact 
tests were used to determine incidence of abdominal pain. The treatment effect was reported as 
mean ± SD; the tilactase group experienced a change in symptom score from 8.05 ± 1.05 
(baseline) to 2.00 ± 1.38 (after treatment), while the placebo group score changed from 7.90 ± 
1.16 (baseline) to 7.10 ± 0.72 (after treatment). P value reported was less than 0.01. Such results 
were interpreted as a large reduction in pain for the patients. 
Table 2 – Efficacy of 9,000 U tilactase in reduction of abdominal pain intensity (data from 
Ojetti et al.6) 
Study group Mean ± SD P value, CI 
9,000 U tilactase baseline 8.05 ± 1.05  
< 0.01, not reported after treatment 2.00 ± 1.38 
Placebo baseline 7.90 ± 1.16 
after treatment 7.10 ± 0.72 
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The De Vrese et al. study7 consisted of five study center visits separated by four two-
week periods. 30 subjects enrolled in the study and were randomly assigned to either a) 9,000 
FCC lactase group, b) 3,300 FCC lactase group, c) placebo group, d) 109 Streptococcus 
thermophilus plus 109 Lactobacillus delbrückii ssp. bulgaricus, e) combination preparation of (b) 
and (d). 1 patient failed to follow up, and 5 patients were not proven to be lactose malabsorbers 
via the hydrogen breath test. A total of 24 patients were included in statistical analysis. As 
displayed in Table 3 below, Friedman test and multiple post hoc Wilcoxon comparisons without 
Bonferroni corrections showed the pain score as 0.4 ± 0.7 (mean ± SD) after 9,000 FCC lactase 
and 0.7 ± 0.9 after placebo treatment. Additionally, the authors report an average 45% of relative 
pain reduction with P value of 0.008. Such statistical values imply a significant statistical effect, 
however, considering that the majority of patients reported abdominal pain symptoms as few and 
mild in intensity (75th percentile score was 1.0 in the 9,000 FCC lactase group and 1.3 in the 
placebo group), the beneficial effect of 9,000 FCC lactase is not well-demonstrated in this study.  
Table 3 – Effect of 9,000 FCC Lactase from Aspergillus oryzae on Abdominal Pain Strength 
(data from De Vrese et al.7) 
Study group Median (25/75th percentile) Mean ± SD Relative % 
pain reduction 
P value, CI 
9,000 FCC lactase 0.0 (0.0/1.0) 0.4 ± 0.7  
45% 
0.008, not 
reported 
Placebo 0.0 (0.0/1.3) 0.7 ± 0.9 
 
Francesconi et al.5 evaluated the participants in four in-person visits to the study center 
on days 0, 14, 28, and 42. 129 persons were randomly assigned to an experimental product group 
(66 patients) and a reference product group (62 patients). Due to consent withdrawal, loss to 
follow-up, adverse effects, and protocol deviation, the experimental group consisted of 64 
patients who received 9,000 FCC Perlatte®- Eurofarma Laboratorios S.A., and the reference 
group included 60 patients treated with 9,000 FCC Lactaid®- McNeilNutritionals, USA. Table 4 
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below summarizes the results from this study. 31% of patients receiving Perlatte®- experienced 
abdominal pain compared to 38% of patients in the reference product group. The NNT value in 
this study was 15, meaning that for every 15 patients with LI treated with preprandial Perlatte®, 
one more case of abdominal pain will be prevented compared to that of Lactaid®. The P value in 
this study, calculated by Fisher’s exact test, was reported to be 0.453 with CI of  
[-31; -3.2] for abdominal pain. This means that, in fact, experimental treatment is not statistically 
different from the reference product. 
Table 4 – Comparison of prevention of abdominal pain between Perlatte® and reference 
product (derived from Francesconi et al.5) 
Control event 
rate (CER) 
Experiment 
event rate 
(EER) 
Relative risk 
reduction 
(RRR) 
Absolute risk 
reduction 
(ARR) 
Number 
needed to 
treat (NNT) 
P value, CI 
0.38 0.31 0.19 0.07 15 0.453, 
[-31; -3.2] 
 
DISCUSSION 
In the U.S., Lactaid (Lactaid, Pleasantville, NJ), Lactodigest (Thompson Medical 
Company, New York, NY), and DairyEase (Glenbrook Laboratories, New York, NY) are widely 
available over-the-counter in drugstores. These supplements contain beta-galactosidase enzyme 
derived from bacteria or yeast. The FDA generally recognizes these products as “safe for human 
consumption,” however, they have not been evaluated for medical treatment of GI symptoms 
caused by lactase deficiency. The generic lactase supplements are also available on the market; 
however, insurance plans require a prescription for coverage of any medication. Moreover, the 
degree of cost reimbursement largely varies by insurance provider.  
Numerous studies have proven efficacy of the preprandial lactase supplement in 
improving the hydrogen lactose breath test results in LI patients as a quantitative marker of LI. 
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However, it has been unclear whether exogenous lactase is indeed an effective treatment for LI 
symptoms such as abdominal pain, nausea, diarrhea, flatulence, and bloating.  
Among the three studies analyzed in this review, the Ojetti et al. study6 conducted in Italy 
demonstrated the most significant reduction in incidence and severity of abdominal pain, proving 
preprandial ingestion of 9,000 U tilactase effective versus placebo. Tilactase also significantly 
reduced diarrhea, bloating, and flatulence. The authors also tested Lactobacillus reuteri as a 
novel approach to LI treatment, but tilactase produced the strongest effect with respect to  
L. reuteri and placebo. It is noteworthy that the subjects in this study were predominantly female, 
and that a thorough demographic profile description was lacking.  
The De Vrese et al. study7 reported a relative reduction in abdominal pain from the 
baseline, however, the individual scores of intestinal complaints did not exceed 1 or 2 on a 0-6 
scale with both 9,000 FCC lactase from Aspergillus oryzae and placebo. Because the study was 
conducted in Germany, where the research ethics rules differ from those in the U.S., the 
administered dose of lactose before the hydrogen breath test constituted 12.5 g instead of the 
U.S. standard of 25 g. Nonetheless, 9,000 FCC lactase had the strongest effect on reducing 
flatulence and not abdominal pain, while abdominal pain was most relieved with a combination 
preparation of 3,300 FCC lactase and 109 S. thermophilus plus 109 L. delbrückii ssp. bulgaricus.  
Francesconi et al.5 revealed the new product Perlatte® to be non-inferior to Lactaid® in 
reducing abdominal pain; yet, the study did not include a placebo group. The authors justified the 
non-inclusion of the placebo group with the statement that Lactaid was known to improve the 
hydrogen breath test results of LI patients. However, Lactaid has not been universally proven to 
reduce abdominal pain or any other GI symptoms from which LI patients suffer. Therefore, 
Perlatte® effectiveness for abdominal pain cannot be concluded. It is also important to note that 
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the study was conducted in Brazil and that the administered dose of lactose prior to the hydrogen 
breath test was 50 g, exceeding the U.S. standard. The authors further reported a conflict of 
interest, as the study was sponsored by the manufacturer. 
 The other important limitation of all three studies, as well as of the search strategy used 
in this systematic review, is a lack of clear differentiation between lactase deficiency and lactose 
malabsorption. For instance, Ojetti et al. did not differentiate between LI patients and lactose 
malabsorbers.6 Lactase deficiency signifies a reduced brush border enzyme activity. Lactose 
malabsorption is determined through the lactose hydrogen breath test. While the two 
aforementioned conditions can be objectively quantified, lactose intolerance comprises a 
syndrome of non-specific GI symptoms and lacks objective verification. Subsequently, because 
abdominal pain cannot be objectively measured, in all three studies it was self-reported via VAS, 
thus leaving room for subjective bias.  
CONCLUSIONS  
 The reviewed studies demonstrated conflicting evidence as to whether preprandial oral 
lactase supplement reduces abdominal pain in LI adult patients after a lactose-containing meal. 
The Ojetti et al. study achieved a marked reduction in abdominal pain after tilactase treatment,6 
while De Vrese et al. reported “relevant” reduction in abdominal pain but not significant.7 The 
Francesconi et al. study proved the new product Perlatte® to be non-inferior to Lactaid and 
demonstrated its potential in treating LI.5  
The majority of published RCTs on LI concentrate on decreasing lactose in the hydrogen 
breath test, however, few studies focus on patient symptoms. None of the latter are known to 
have been conducted and published in the United States. Future research would benefit from the 
following two interventions. First, a thorough demographic profile of the participants should 
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include ethnicity and genetic analysis. Due to the diversity of the U.S. population, this may be a 
key intervention, although the cost and availability of such concomitant genetic testing in the 
U.S. may present difficulties for the research. Second, the study participants should have an 
established diagnosis of lactose malabsorption or lactase deficiency. While there is an overlap 
between the two conditions, and indeed both patient groups may present with LI symptoms, not 
all lactose malabsorbers qualify for lactase deficiency diagnosis.  
Overall, exogenous lactase seems to be a promising therapy and potential first-line 
treatment for LI, which could replace dietary restriction and improve the quality of life of 
patients with intolerance to lactose.  
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